Monte Rosa Therapeutics (GLUE) Share-based Compensation (2020 - 2026)

Monte Rosa Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $49.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 832.43% year-over-year to $49.4 million in Q1 2026; TTM through Mar 2026 was $49.4 million, a 166.29% increase from a year earlier, with the FY2025 full-year figure at $24.2 million, up 4.31% from the prior year.
• Share-based Compensation climbed to $49.4 million in Q1 2026 per GLUE's latest filing, from $4.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $49.4 million in Q1 2026 and bottomed at $100000.0 in Q2 2023.
• The 5-year median for Share-based Compensation is $4.4 million (2025), against an average of $9.9 million.
• Biggest YoY gain for Share-based Compensation was 16450.0% in 2023; the steepest drop was 99.72% in 2023.
• Year by year, Share-based Compensation stood at $3.3 million in 2022, then grew by 22.49% to $4.1 million in 2023, then climbed by 9.7% to $4.5 million in 2024, then decreased by 3.58% to $4.3 million in 2025, then soared by 1046.44% to $49.4 million in 2026.
• Per Business Quant, the three latest GLUE Share-based Compensation figures stand at $49.4 million (Q1 2026), $4.3 million (Q4 2025), and $4.4 million (Q3 2025).